Insights on the use of biosimilars in the treatment of inflammatory bowel disease

doi:10.3748/wjg.v23.i11.1932

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9716)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

996

WORD

390

HTML

5453

Tables (1-3)

266

Sum=7105

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1061

Download

1550

Sum=2611

Mar 21, 2017 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Mar 21, 2017; 23(11): 1932-1943
Published online Mar 21, 2017. doi: 10.3748/wjg.v23.i11.1932

Table 2 Proposed anti-tumor necrosis factor biosimilars¹

Reference medicinal product	Biosimilar name
Infliximab	Infliximab-dyyb (Celltrion)²
	SB2 (Samsung Bioepis)
	PF-06438179 (Sandoz)
	BOW015 (Epirus)
Adalimumab	Adalimumab-atto (Amgen)²
	SB5 (Samsung Bioepis)
	ZRC-3197 (Zydus Cadila)
	MSB11022 (Merck KGaA)
Certolizumab pegol	PF688 (PFEnex)
Golimumab	BOW100 (Epirus)

¹Information for each biosimilar was derived from the website of its respective drug company;

²Approved by the United States Food and Drug Administration.

Citation: Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(11): 1932-1943
URL: https://www.wjgnet.com/1007-9327/full/v23/i11/1932.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i11.1932